INTRODUCTION {#s1}
============

Cholangiocarcinoma (CCC), a rare tumor that arises from the bile duct, accounts for only 3% of all gastrointestinal cancers^[@R1]^ and 15% of liver cancers.^[@R2]^ The prognosis for CCC is particularly poor when presenting with unresectable anatomy (5-year survival of approximately 12%).^[@R3]^ However, treatment with Whipple duodenopancreatectomy is possible in 67% of patients with extrahepatic CCC,^[@R3],[@R4]^ and this treatment option increases the 5-year survival rate from 12% to 28%.^[@R4]^ In studies by He and Wu (2008) and by Ramírez-Merino et al (2013), radiotherapy and chemotherapy were trialed with questionable efficacy.^[@R5],[@R6]^ CCC is known to metastasize most commonly to the liver, peritoneum, intraabdominal lymph nodes, and lungs.^[@R7]^ Bone metastases are relatively less common^[@R8]^ and most frequently occur in the distal skeleton.^[@R9]^ Concurrent metastasis to the spine and cranium is an exceedingly rare phenomenon with few reported cases to date.^[@R3],[@R10]-[@R15]^

Metastasis of CCC to the cranium and spinal column is hypothesized to occur through 2 main pathways: (1) the osseous pathway via the craniospinal venous system (CSVS)^[@R16],[@R17]^ and (2) hematogenous spread via the pulmonary vasculature to seed the axial skeleton and brain.^[@R10],[@R12]^ The CSVS has 2 major divisions: (1) the vertebral venous system that includes the Batson plexus^[@R16]^ and (2) the intracranial veins that include the cavernous sinuses, the cortical veins, the dural sinuses, and the ophthalmic veins.^[@R17]^ The anatomy of the CSVS includes veins that exist without valves, allowing bidirectional flow^[@R16],[@R18]^ with increased intraabdominal or intrathoracic pressure.^[@R16]-[@R18]^ Retrograde venous flow within the CSVS is currently the most supported theory for CCC metastasis to the cranium and spine as per Fujimoto et al, who demonstrated metastasis along the lines of the CSVS.^[@R10]^

Definitive diagnosis of CCC metastasis to the spine and cranium is reserved for pathology and immunohistochemistry, as radiologic imaging and clinical presentation are nonspecific. Despite poor specificity, positron emission tomography (PET) offers significant advantages as a method of detecting metastases,^[@R10],[@R12]^ with methionine PET showing higher sensitivity than fluorodeoxyglucose PET.^[@R10]^ Magnetic resonance imaging (MRI) classically shows a heterointense honeycomb appearance on both T1- and T2-weighted imaging and may be used to assist in the planning of surgical resection.^[@R12]^ Common presenting symptoms are also largely nonspecific and may vary by location. Metastasis to the skull is typically asymptomatic but may cause severe disability with compression of the dural sinuses,^[@R19]^ disturbance of the cranial nerves,^[@R20]^ epidural hematoma,^[@R21]-[@R23]^ and expansion of the tumor secondary to intratumoral hemorrhage.^[@R24]^ Metastasis to the spine may present as neck pain,^[@R11]^ back pain,^[@R15]^ periscapular pain,^[@R3]^ or even complete neurologic syndrome.^[@R25]^ On cytologic examination, smears reveal a glandular arrangement of crowded clusters and sheets of malignant cells with large nuclei and prominent nucleoli.^[@R11]^ Immunohistochemistry of metastatic CCC cells shows strong immunopositivity for cytokeratin (CK)-7 and CK-19, AE1/AE3, CAM 5.2, MOC-31, and polyclonal carcinoembryonic antigen (pCEA).^[@R11],[@R26]^ Equally important is the immunonegativity for thyroid transcription factor-1 (TTF-1), prostate-specific antigen (PSA), and CK-20 that helps to rule out metastasis from the lung, prostate, and colon, respectively.^[@R11]^

While documented evidence of CCC spine metastasis was previously limited, case series published between 2001 and 2018---largely from Thailand and South Korea---demonstrate hundreds of cases of CCC metastasis to the spine,^[@R3],[@R10]-[@R13],[@R15],[@R27]-[@R31]^ yet only 6 cases of metastasis to the cranium have been reported,^[@R10],[@R12],[@R14],[@R32]^ and only 2 of those cases coinvolved the spine and cranium.^[@R10],[@R12]^ We present a case of combined CCC metastasis to the cranium and spine.

CASE REPORT {#s2}
===========

A 61-year-old male presented with a 1-month history of increasing back pain that he associated with muscle spasm. The patient reported that the pain started gradually and had progressed to a 7/10 on the pain scale by the time he presented to the hospital. The patient\'s significant medical history included a liver transplant 9 months prior secondary to chronic hepatitis C. At the time of the patient\'s transplant, pathologic review of the explant was notable for a 0.6-cm pure hepatocellular carcinoma and a 0.7-cm mixed cholangiocarcinoma with hepatocellular carcinoma components, both confined to the right lobe of the liver. No adjuvant treatment was undertaken at the time of transplant, as both lesions were without lymphovascular invasion. Physical examination showed a palpable nontender mass in the parieto-occipital area but was otherwise unremarkable.

Computed tomography (CT) imaging of the spine revealed mixed sclerotic/lytic lesions involving T9 and T11 (Figures [1A](#f1){ref-type="fig"} and [1B](#f1){ref-type="fig"}) and L2 and L5; an additional lytic lesion was seen in the T6 vertebral body ([Figure 1C](#f1){ref-type="fig"}). The T11 vertebral body appeared almost entirely replaced by sclerotic focus; the T9/T10 levels demonstrated extension into the central canal; and the lesion in the T6 vertebral body measured 1.7 cm. CT imaging of the head revealed a focal well-defined erosive lesion within the right occipital calvarium that measured approximately 1.4 cm and likely involved the inner and outer tables of the calvarium ([Figure 2](#f2){ref-type="fig"}). Associated with this lesion was overlying soft tissue prominence concerning for extraosseous extension measuring 9 mm in thickness. No apparent local reaction in the brain was noted, and the cerebral parenchyma appeared otherwise unremarkable. MRI was not done at this time.

![**Sagittal computed tomography sections without contrast of the thoracic spine demonstrate multiple mixed sclerotic/lytic lesions involving the T9 and T11 vertebral bodies (A and B), with a lytic lesion at T6 (C). Lumbar lesions are not shown.**](toj-18-0142-figure1){#f1}

![**Computed tomography head with contrast. Sagittal (left) and axial (right) views demonstrate a 1.4-cm focal bony erosive lesion in the right occipital calvarium with ill-defined margins. Deformity and defect extend through both tables of the calvarium.**](toj-18-0142-figure2){#f2}

The patient underwent a right occipital craniotomy with stealth navigation for excisional biopsy of the mass. Intraoperative visualization and resection of the tumor revealed a 1.4-cm red-brown mass that extended through both tables of the skull. The mass was adherent with but not attached to the dura and was easily scraped away. Special care was taken to clean and coagulate the involved dura. Resection was completed with bone edges free of tumor involvement, and the lesion was fully contained within the craniotomy excision. Pathology results demonstrated a metastatic adenocarcinoma virtually identical to the cholangiocarcinoma component seen in the patient\'s liver explant 9 months prior ([Figure 3](#f3){ref-type="fig"}). Immunohistochemistry showed focal CK-7 positivity and negativity to hepatocyte antigen, CK-20, synaptophysin, and chromogranin. Postoperative imaging demonstrated complete resection of the cranial lesion. The patient progressed without complications and was discharged 4 days later.

![**Histopathology hematoxylin and eosin stains of the primary tumor initially found in the right lobe of the liver (A and B). Histopathology hematoxylin and eosin stains of the metastatic adenocarcinoma excised from the calvarium (C and D).**](toj-18-0142-figure3){#f3}

The patient was started on cisplatin 25 mg/m^2^ and gemcitabine 1,000 mg/m^2^ infusions the same day as his craniotomy; he had a second and final chemotherapeutic treatment 1 week postoperatively. One month following his operation, the patient began a course of radiation to a dose of 30 Gy in fractions of 3 Gy that targeted the metastases to the thoracic spine and the L5 vertebral body. The patient continued follow-up with neurosurgery following his operation; however, he succumbed to his illness and died from complications of the metastatic disease 3 months postoperatively.

DISCUSSION {#s3}
==========

Metastases from CCC display unique cytologic and immunohistochemical properties that aid in diagnosis^[@R11],[@R26]^ but present with nonspecific symptoms^[@R3],[@R15],[@R19]-[@R25]^ and imaging.^[@R10],[@R12]^ Metastasis to the spine and/or cranium is rare; however, a small number of cases with spinal and cranial metastasis have been documented in the literature in case reports ([Table 1](#t1){ref-type="table"})^[@R3],[@R10]-[@R15]^ and in retrospective clinical studies and review articles ([Table 2](#t2){ref-type="table"}).^[@R27]-[@R32]^

###### 

Characteristics of Patients in Case Reports of Axial Cholangiocarcinoma Metastasis

                                         Age in                                                                                                                                    Metastasis   Surgical
  -------------------------------------- -------- ---------------------------------------------------------------- ---------- ---------------------------------------------------- ------------ ---------------------
  Current case                           61, M    Back pain                                                        9 months   Right occipital bone, T9-T11, L2, L5                 No           Yes, cranial lesion
  Faugeras et al,^[@R3]^ 2015            62, M    Pain in scapula                                                  2 years    L2, C4                                               Yes          No
  Purushothaman et al,^[@R13]^ 2015      40, F    Neck pain                                                        Unknown    C6-T2                                                No           No
  Fujimoto et al,^[@R10]^ 2013           56, F    Painful mass in right parietal region                            3 years    Left orbit, left parietal bone, left temporal bone   No           No
  Fujimoto et al,^[@R10]^ 2013           58, F    Pain and swelling in left orbit                                  2 months   Left orbit, right parietal bone                      No           No
  Fujimoto et al,^[@R10]^ 2013           65, M    Pain in right occipital region with right IX, X, XI, XII palsy   2 months   Right petrous bone, C1                               No           No
  Kidambi et al,^[@R11]^ 2011            82, M    Progressive neck pain                                            2 months   C3, C4, T3-T5                                        No           Unknown
  Wojtas and Deinsberger,^[@R14]^ 2009   72, F    Headache                                                         2 years    Cranium, unspecified                                 No           Yes
  Miyamoto et al,^[@R12]^ 2007           67, F    Painful subcutaneous lesion in parietal region                   2 years    Left occipital bone, T12                             No           Yes, cranial lesion
  Yeh et al,^[@R15]^ 2001                63, F    Low back pain                                                    2 years    T12                                                  No           Yes

CNS, central nervous system; F, female; M, male.

###### 

Characteristics of Patients in Studies (Other Than Case Reports) of Axial Cholangiocarcinoma Metastasis

                                   Number of   Median   Most Common                                                      Most Common        Metastasis
  -------------------------------- ----------- -------- ---------------------------------------------------------------- ------------------ ------------
  Sangsin et al,^[@R27]^ 2018      182         57       Jaundice, hepatomegaly, palpable gallbladder and/or liver mass   Multilevel spine   No
  Dowsiriroj et al,^[@R28]^ 2017   55          57       Neurologic deficit (Frankel scale grade C or lower)              Thoracic spine     No
  Turel et al,^[@R31]^ 2017        2           57.5     Inability to ambulate                                            L2/S1              No
  Goodwin et al,^[@R29]^ 2016      16          55.5     Pain                                                             Multilevel spine   No
  Singh et al,^[@R32]^ 2015        4           61.5     Pain                                                             Cranium            No
  Paholpak et al,^[@R30]^ 2012     15          57.5     N/A                                                              Thoracic spine     No

CNS, central nervous system; N/A, not available.

Yeh et al described the first incidence of CCC metastasis to the spine in 2001,^[@R15]^ followed by the first reported case of skull metastasis by Miyamoto et al in 2007.^[@R12]^ Including our own patient, there are currently 9 known cases of CCC metastasis to the spine in the United States,^[@R3],[@R10]-[@R13],[@R15],[@R31]^ with hundreds more reported in Eastern Asia, and 7 cases of metastasis to the cranium^[@R10],[@R12],[@R14],[@R32]^ with 3 combined cases of spine/cranium metastasis including our own.^[@R10],[@R12]^ In these cases, the average patient age was 60.1 years with a range of 38 to 82 years and a female:male ratio of approximately 1:1 ([Tables 1](#t1){ref-type="table"} and [2](#t2){ref-type="table"}).

Although it is tempting to believe that spinal/cranial metastasis from CCC is a novel presentation of an existing tumor entity, we posit that the historic absence of immunohistochemistry to aid in past diagnoses may have obscured previous cases in the literature. Other sources argue that the increasing incidence of these less common metastatic sites may be attributable to an increase in overall survival of patients secondary to the advent of multimodal therapies.^[@R3]^ This increase in incidence is supported by studies from 2010 and 2013^[@R3],[@R33]^ that correlated prolonged overall survival and progression-free survival with modern management strategies, particularly the use of cisplatin and gemcitabine in palliative situations. This theory is supported by the fact that 6 patients, including our own, had prolonged latency periods between the original presentation of CCC and metastasis to the spine and/or cranium. However, 4 patients presented with metastasis concomitant with the discovery of their primary neoplasm.^[@R10]-[@R15]^

Pending definitive diagnosis with cytology and immunohistochemistry, the 4 treatments for metastatic CCC are surgery, radiation, chemotherapy, and hormonal therapy.^[@R10]^ Of these, surgical excision is most commonly employed for symptomatic lesions, provided the lesion can be removed with little risk of morbidity or mortality.^[@R19],[@R34],[@R35]^ The goal of surgery in metastatic disease is to offer local control and symptomatic relief, with no expected change in overall prognosis.^[@R25],[@R35]^ When lesions are too extensive or too difficult to resect, radiotherapy may be applied.^[@R10]^ Radiotherapy with or without chemotherapy was found to provide pain relief in up to 90% of patients with symptoms of short duration.^[@R36]^ Chemotherapy and hormonal therapy are considered to be the least effective treatments overall^[@R3],[@R5],[@R6],[@R10]^; however, in studies from 2011 and 2017, the use of gemcitabine and cisplatin together demonstrated positive effects on systemic lesions and potential clinical improvement.^[@R28],[@R37]^

As mentioned previously, the use of Whipple duodenopancreatectomy in extrahepatic CCC has increased the overall 5-year survival rate from 12% to 28% in local disease.^[@R4]^ However, improvements have also been found in metastatic disease. In CCC with metastasis, median survival is currently 7 to 12 months, with a 2013 study from Ramírez-Merino et al showing even longer overall survival and progression-free survival with newer treatment regimens.^[@R6]^ Still, the exact impact of cranial and/or spinal metastases on disease progression, morbidity, and mortality has yet to be established. The authors anticipate a negative prognostic effect secondary to the neurologic sequelae described in this report.

CONCLUSION {#s4}
==========

CCC is a rare visceral tumor, not classically associated with spread to the spine and/or cranium. CCC metastasis is indistinguishable from more common primary tumor types by clinical or radiologic findings, making preoperative diagnosis impossible without the assistance of pathologic study. CCC metastasis to the cranium or spine has indeterminate impact on the disease course and prognosis, although our own experience demonstrates a poor prognostic outcome. Upon diagnosis, treatment of metastatic sites is considered solely palliative but may be combined with curative measures. This case supplements the existing literature to inform medical and surgical decision-making.
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